Skip to content
Companies

OraLiva

Point-of-care cytology tests for oral cancer

Raised to date

$1.5M

of $2.3M offered across 1 Form D filing

Still open
$750K
Investors
1
Last filed
Mar 21, 2025

About

OraLiva, Inc. is an innovative medical technology company specializing in the development of advanced early detection diagnostics for oral cancer. By leveraging cutting-edge technology, the company aims to address the critical issue of late-stage cancer diagnosis, enhancing patient outcomes through timely intervention.

OraLiva stands out for its clinically validated, AI-linked diagnostic platform that allows for noninvasive and rapid cancer detection directly at the point of care.

Funding

  • Security to be acquiredFiled Mar 21, 2025Form D
    $1.5M/ $2.3M

Product

ONC-InCyt Technology

Diagnostic Technology

The ONC-InCyt technology is a portable, programmable cytology platform designed for point-of-care use. This advanced diagnostic tool utilizes a microfluidic engine to process cells and deliver reliable diagnostics for oral cancer and oral dysplasia.

  • Noninvasive and painless procedure
  • High sensitivity and specificity in cancer detection
  • AI-linked diagnostic capabilities

Built for

Healthcare professionals, specifically in dentistry and ENT

People on file